The primary therapeutic role of Biosulin 30/70 is commonly used as insulin replacement therapy for the management of Diabetes Mellitus in adults and children who require insulin for glycemic control. It is applied in situations where a lack of the body's natural hormone creates a systemic imbalance.

This fixed-ratio premix is a therapeutic option aligned with domains involving significant symptom expression, which supports the process of improving blood sugar control. The medicine is commonly used for managing both Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus, relevant in conditions where functional stability becomes affected by the progression of the disease.

The biphasic formulation is considered relevant for managing symptoms that interfere with daily functioning by assisting with the dual challenge of elevated fasting glucose and postprandial (after-meal) sugar spikes. This provides support that helps ease the overall symptom burden and may help manage the long-term risk of complications associated with the disease.

---

Quick Fact: Relief for Dual Hyperglycemia

This product is commonly used to help with managing both persistent, high baseline sugar levels and the acute sugar surges that often follow meals, applying a dual action for symptomatic management.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and pediatric patients with Diabetes Mellitus who require insulin for glycemic control.
Populations for whom use is contraindicated	Individuals experiencing Hypoglycemia (low blood sugar) and those with known Hypersensitivity to human insulin or any excipients.
Age-related eligibility rules	Adults are the primary established population. Use in pediatric patients is indicated, though some regulatory labels note that safety and effectiveness in patients under 18 years of age are not fully established. Older adults may be used with caution and require intensified glucose monitoring.
Condition-specific eligibility rules	Patients with Renal or Hepatic Impairment are eligible for treatment, but their insulin requirements may be reduced. Use requires intensified glucose monitoring and close medical supervision.
Pregnancy and lactation eligibility status	Use is permitted during pregnancy and lactation; insulin does not pose a risk to the infant. However, maternal dosage adjustments are typically required due to changing metabolic needs.

Connection to the overall eligibility profile

The regulatory profile strictly limits the use of this medicine by establishing two absolute prohibitions (contraindications): existing hypoglycemia and known hypersensitivity to the product. All other populations, including those with certain physiological limitations like renal or hepatic impairment, are considered eligible but require documented precautions and intensified glucose monitoring, as specified in the official prescribing information.

Interactions with other medicines and products

Official regulatory documents classify interactions with Biosulin 30/70 (Insulin Human Biphasic) based primarily on the substance's effect on blood sugar levels, which impacts the insulin requirement.

Interaction Type	Examples of Documented Interacting Substances
Enhancing the Glucose-Lowering Effect (May reduce insulin requirements)	Oral Antidiabetic Agents, MAOIs, ACE inhibitors, Beta-blockers (may also mask hypoglycemia symptoms), Salicylates, Sulfonamide antibiotics, Anabolic steroids.
Reducing the Glucose-Lowering Effect (May increase insulin requirements)	Glucocorticoids (Corticosteroids), Thiazide diuretics, Thyroid hormones, Oral Contraceptives, Sympathomimetics, Growth hormone, Niacin.
Non-Glycemic Risk (Specific Co-administration Warning)	Thiazolidinediones (TZDs): Co-administration is associated with a specific regulatory warning for fluid retention and increased risk of cardiac failure.

Official prescribing information notes that consumption of alcohol may either intensify or reduce the blood sugar lowering action of insulin. Furthermore, patient conditions such as Hepatic Impairment and Renal Impairment are documented to potentially reduce insulin requirements due to altered drug clearance, constituting a population-specific interaction consideration.

Administration of Biosulin 30/70 is formally contraindicated during an active episode of hypoglycemia.

Molecular Mechanism: Glucose Uptake and Signaling

Biosulin 30/70 is a formulation of human insulin that influences glucose metabolism through a dual-mechanism of action. The mechanism begins with the insulin component acting as an agonist by binding to the Insulin Receptor (IR) on the surface of muscle and fat cells. This binding activates an intracellular cascade, causing GLUT4 glucose transporters to translocate to the cell membrane. This event facilitates the uptake of glucose from the bloodstream, a pathway crucial for glucose clearance from circulation.

Hepatic Regulation and Biphasic Kinetics

In the liver, the insulin component targets enzyme systems to exert a dual regulatory function: it suppresses gluconeogenesis (glucose creation) and glycogenolysis (glycogen breakdown), while simultaneously promoting glycogen synthesis (glucose storage). This modulation influences the basal rate of hepatic glucose output. The drug's pre-mixed composition (30% soluble insulin and 70% Isophane insulin) provides a differential absorption profile, establishing both a rapid signaling wave and a prolonged, sustained mechanistic activity.

Instruction Map: How to use Biosulin 30/70 — Official Administration Guidelines

Administration Scope	Detail
Route of Administration	Subcutaneous (SC) injection only. Do not administer intravenously or intramuscularly; do not use in an insulin infusion pump.
Dosing Schedule	Dosage must be individualized by a healthcare provider based on the patient’s metabolic needs and blood glucose monitoring results. It is typically dosed twice daily (to cover two meals or a meal and a snack).
Timing in Relation to Meals	Inject the prescribed dose subcutaneously approximately 30 minutes prior to the start of a meal.
Preparation Requirements	The suspension must be resuspended immediately before use by gently rolling or shaking until it appears uniformly white and cloudy. Do not use if particulate matter or flocculation is observed. Do not mix with any other insulins or diluents.
Special Procedural Conditions	Rotate the injection site within the abdominal wall, thigh, upper arm, or buttocks to reduce the risk of lipodystrophy. The disposable pen or syringe must never be shared with other patients due to the risk of transmitting blood-borne pathogens.
Missed Dose Rule	If a dose is missed, contact a healthcare provider for instructions.

Official Procedural Steps

1. Inspect and Resuspend: Check the insulin before each use; it must be uniformly cloudy. Resuspend immediately before injection by rolling/shaking gently.
2. Select Site: Inject into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks.
3. Rotate Site: Continuously rotate the injection site within the selected region from one injection to the next.
4. Administer: Inject the dose approximately 30 minutes before consuming a meal.

Connection to the Overall Use Protocol The fixed-ratio Biosulin 30/70 is administered subcutaneously on a highly individualized, typically twice-daily schedule. The strict requirement to resuspend the product and inject it precisely before a meal is fundamental to the protocol, ensuring the intermediate and short-acting components are delivered correctly to manage glucose levels post-meal and provide basal coverage.

Biosulin 30/70 is a biphasic insulin formulation composed of 30% regular human insulin (short-acting) and 70% Isophane NPH human insulin (intermediate-acting). This premixed combination is designed to help manage blood glucose levels in adults and children with Type 1 and Type 2 diabetes mellitus by providing both rapid-onset and sustained insulin action.

Efficacy and Glycemic Control

Clinical trials have investigated the effectiveness of biphasic human insulin formulations, including biosimilar versions like Biosulin 30/70, primarily focusing on maintaining target glycated hemoglobin (HbA1c) levels. The main goal in the management of diabetes is the reduction of HbA1c, fasting plasma glucose (FPG), and postprandial glucose (PPG) excursions.

• HbA1c Reduction: Studies have indicated that the use of Biosulin 30/70, when compared to other human premixed insulin preparations or used in a treat-to-target approach, is associated with a reduction in HbA1c values. A study examining a transition from existing premixed human insulins to Biosulin 30/70 in a clinical setting suggested that the compound achieved at least equivalent glycemic control.
• Postprandial Control: The presence of the short-acting regular insulin component is intended to address the blood glucose increase following meals, contributing to improved postprandial glucose control compared to intermediate-acting NPH insulin alone.

Safety and Tolerability Observations

The most commonly reported adverse event associated with all insulin therapies, including Biosulin 30/70, is hypoglycemia (low blood sugar), which is a key safety consideration requiring regular glucose monitoring.

Additional safety observations noted in trials and clinical experience for this class of product include:

Observation Category	Reported Findings
Injection Site	Local reactions, such as pain, swelling, or redness, may be observed.
Metabolic	Minor weight gain was noted in some participants during the course of the studies.

Switching from other insulin regimens to Biosulin 30/70 requires careful medical supervision, as the individualized insulin dose may need adjustment based on the patient's specific metabolic profile and glucose monitoring data.

Key Studies & References Novolin 70/30 (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection) Prescribing Information (Reference Product Label)

Common questions about Biosulin 30/70 (FAQ)

---

Q: Is Biosulin 30/70 a rapid-acting or long-acting insulin?

Biosulin 30/70 is described in official product information as a biphasic product. This means it is a mixture containing two types of human insulin: a short-acting component that works quickly, and an intermediate-acting component (Isophane) that provides a prolonged, sustained effect. Its dual nature means it is not solely classified as a rapid-acting or long-acting insulin.

Q: Can I use Biosulin 30/70 if I have kidney problems?

Regulatory documents state that use in individuals with kidney problems (renal impairment) is possible. The patient population with reduced kidney function requires close monitoring of blood sugar levels as noted in official guidance. This is because altered drug clearance may change the insulin requirements.

Q: What are the most common side effects reported for Biosulin 30/70?

According to official documentation, the most frequently reported adverse event is low blood sugar, known as hypoglycemia. Common side effects reported in official documentation may also include injection site reactions and changes in fat tissue (lipodystrophy).

Q: What medicines should not be taken while using Biosulin 30/70?

Biosulin 30/70 is formally prohibited (contraindicated) when a patient is experiencing an episode of low blood sugar or has a known hypersensitivity to the product. Co-administration with Thiazolidinediones (TZDs) is associated with a specific regulatory warning due to the potential for fluid retention and increased risk of heart failure.

Q: Are there any known severe side effects of Biosulin 30/70?

Officially documented serious adverse reactions include severe low blood sugar (severe hypoglycemia), which is noted for its potential severity. Rare but potentially widespread allergic reactions (systemic hypersensitivity) are also noted in safety data.

Q: Is Biosulin 30/70 safe for people over 65?

Official information indicates that use is allowed in older adults. However, regulatory documents advise that this population may require intensified blood sugar monitoring. This is due to an increased susceptibility to low blood sugar (hypoglycemia) in this population.

Q: Is Biosulin 30/70 the same as other insulins?

No. Biosulin 30/70 is a specific biphasic insulin formulation. This fixed combination contains both short-acting and intermediate-acting human insulin. This specific mixture and ratio (30% to 70%) is a key defining characteristic.

Q: How quickly does Biosulin 30/70 start working?

Based on official pharmacological data for this type of formulation, the blood sugar lowering effect typically begins approximately 30 minutes after the subcutaneous administration.

Q: How long does the effect of Biosulin 30/70 last?

According to official sources, the overall blood sugar lowering effect of Biosulin 30/70 is documented to last for up to 24 hours following a single subcutaneous injection.

Q: What are the ingredients in Biosulin 30/70 besides insulin?

Official labeling for this formulation lists a number of excipients (inactive ingredients) in addition to human insulin. These typically include substances such as water, zinc chloride, glycerol, metacresol, phenol, disodium phosphate dihydrate, and protamine sulfate.

Q: Can Biosulin 30/70 affect my blood pressure?

Official warnings note a significant circulatory risk involving fluid retention and the potential for increased risk of heart failure when Biosulin 30/70 is used with certain other antidiabetic medicines (TZDs). Additionally, low potassium (hypokalemia) is noted as a potential side effect.

Q: What is the difference between Biosulin 30/70 and other insulin mixtures?

Biosulin 30/70 is defined by its fixed ratio of 30% short-acting insulin and 70% intermediate-acting insulin. This specific ratio, combined with the fact that its active compound is Human Insulin (not a synthetic analogue), is the key distinction.

Q: Can I drive or operate machinery while using Biosulin 30/70?

Official warnings state that a patient's ability to perform complex tasks, such as driving or operating machinery, should be considered. This consideration is primarily due to potential fluctuations in blood sugar, specifically if levels become too low (hypoglycemia) or too high (hyperglycemia).

Q: Does using Biosulin 30/70 require changes to my diet?

Official information indicates that dosage adjustments may be needed if there are changes in a patient's physical activity, body weight, or consistent meal patterns. This reflects the necessity of aligning the dose with a patient's metabolic needs.

Q: Is Biosulin 30/70 associated with any long-term effects?

Lipodystrophy (changes in fat tissue at the injection site) is associated with long-term exposure if injection sites are not regularly rotated. Conversely, achieving and maintaining long-term glycemic control is associated with reduced risk of diabetes-related complications, as noted in general studies.

Q: Are there any known drug-drug interactions for Biosulin 30/70?

Yes, regulatory documents list many other substances that can affect the action of insulin. Some medicines may enhance its blood sugar lowering effect, while others may reduce the effect.

Q: Can I travel internationally with Biosulin 30/70?

When traveling, it is important to adhere to the product’s specific storage requirements, particularly keeping it refrigerated and preventing it from freezing. Official guidance regarding travel notes the importance of carrying medical documentation and prescriptions.

Q: Does Biosulin 30/70 work differently in different people?

Official product documentation emphasizes that the prescribed dosage must be highly individualized for each person. This necessity for tailored dosing, based on the patient’s metabolic needs and monitoring results, indicates that requirements and responses vary among individuals.

Q: What is the purpose of the neutral protamine in Biosulin 30/70?

The protamine is a small protein added to the intermediate-acting (Isophane) component. It combines with the insulin to form crystals that dissolve slowly after injection. This process helps delay the insulin's release, contributing to the intermediate-acting and prolonged effect.

Q: Do studies track the long-term effectiveness of Biosulin 30/70?

Studies for this class of product examine effectiveness by tracking maintenance of target glycated hemoglobin (HbA1c) levels. HbA1c provides a measure of average blood sugar control over an extended period, which is the key indicator of long-term effectiveness.

Q: What is the official chemical class of Biosulin 30/70?

The active compound, Insulin Human Biphasic, is officially classified as an Insulin and a Hypoglycemic Agent (Insulin Preparation) within the pharmacological class hierarchy defined by regulatory bodies.

Q: Are there different forms (pen/vial) of Biosulin 30/70?

Yes, this product is generally available as an injectable suspension in more than one format. It is typically supplied in both multiple-dose vials and prefilled single-patient-use pen devices.

Q: Is it normal to feel tired after starting Biosulin 30/70?

Tiredness or fatigue is not listed as a frequently reported adverse event in official documentation. However, fatigue is a known symptom of low blood sugar (hypoglycemia), which is the most frequent adverse event associated with insulin use.

Q: What should I do if I miss a use of Biosulin 30/70?

According to the official administration rules, if a use (dose) is missed, the patient should contact a healthcare provider for instructions on how to proceed. The official administration rules state that specific guidance is provided by a medical professional.

Q: Are there any foods or drinks that interact with Biosulin 30/70?

Official documents specifically mention that consumption of alcohol may either intensify or reduce the blood sugar lowering action of insulin. In general, changes to a patient's meal patterns necessitate careful consideration for dosage adjustment.

---

Storage and Disposal Requirements for Biosulin 30/70

Unopened Biosulin 30/70 must be stored refrigerated at a temperature between 2 C and 8 C (36 F and 46 F). The product must be kept in the original outer carton to protect it from light and must not be frozen; any product that has been frozen must be discarded.

---

In-Use Stability and Handling

Once opened, a vial is stable for up to 42 days (6 weeks) at room temperature, provided the temperature remains below 25 C (77 F). Pens are stable for up to 28 or 31 days. After these periods, the product must be discarded. The medicine must be kept out of the reach of children.

---

Disposal of Used Sharps

Used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container. Loose sharps must not be thrown away in household trash. Disposal of the full sharps container must follow local regulations.